Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 1.5x - 1.6x | 1.5x |
| Selected Fwd Ps Multiple | 46.2x - 51.1x | 48.6x |
| Fair Value | $1.16 - $1.29 | $1.23 |
| Upside | 59.0% - 75.8% | 67.4% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Dyadic International, Inc. | - | NasdaqCM:DYAI |
| Onconetix, Inc. | - | NasdaqCM:ONCO |
| Cardiff Oncology, Inc. | - | NasdaqCM:CRDF |
| Geron Corporation | - | NasdaqGS:GERN |
| Trevena, Inc. | - | OTCPK:TRVN |
| Spero Therapeutics, Inc. | - | NasdaqGS:SPRO |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| DYAI | ONCO | CRDF | GERN | TRVN | SPRO | |||
| NasdaqCM:DYAI | NasdaqCM:ONCO | NasdaqCM:CRDF | NasdaqGS:GERN | OTCPK:TRVN | NasdaqGS:SPRO | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 15.8% | NM- | 22.8% | 178.4% | -11.4% | 21.5% | ||
| 3Y CAGR | 13.3% | NM- | 23.9% | 280.9% | 0.6% | 38.0% | ||
| Latest Twelve Months | 20.6% | NM | 40.0% | 32386.9% | -83.0% | -53.8% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -404.2% | -19098.5% | -7594.3% | -23982.0% | -19680.3% | -408.4% | ||
| Prior Fiscal Year | -234.4% | NA | -8496.9% | -77690.7% | 12839.7% | 22.0% | ||
| Latest Fiscal Year | -166.2% | -63986.5% | -6655.2% | -226.7% | -1289.2% | -142.9% | ||
| Latest Twelve Months | -166.2% | -2758.7% | -6655.2% | -226.7% | -6233.7% | -142.9% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | NA | -1.3x | -2.3x | -3.2x | -0.8x | 0.1x | ||
| Price / LTM Sales | 10.4x | 0.3x | 297.1x | 12.2x | 2.0x | 0.9x | ||
| LTM P/E Ratio | -6.3x | 0.0x | -4.5x | -5.4x | 0.0x | -0.6x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.3x | 10.4x | 297.1x | |||||
| Historical LTM P/S Ratio | 0.9x | 10.2x | 47.7x | |||||
| Selected Price / Sales Multiple | 1.5x | 1.5x | 1.6x | |||||
| (x) LTM Sales | 48 | 48 | 48 | |||||
| (=) Equity Value | 70 | 74 | 77 | |||||
| (/) Shares Outstanding | 55.9 | 55.9 | 55.9 | |||||
| Implied Value Range | 1.25 | 1.32 | 1.39 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 1.25 | 1.32 | 1.39 | 0.73 | ||||
| Upside / (Downside) | 71.2% | 80.3% | 89.3% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | DYAI | ONCO | CRDF | GERN | TRVN | SPRO | |
| Value of Common Equity | 36 | 0 | 203 | 898 | 1 | 41 | |
| (/) Shares Outstanding | 30.1 | 8.3 | 66.5 | 636.9 | 0.9 | 55.9 | |
| Implied Stock Price | 1.21 | 0.06 | 3.05 | 1.41 | 1.27 | 0.73 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1.21 | 0.06 | 3.05 | 1.41 | 1.27 | 0.73 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |